ProMetic Life Sciences Inc. (PLI) Director Nancy Orr-Gaucher Purchases 17,200 Shares
ProMetic Life Sciences Inc. (TSE:PLI) Director Nancy Orr-Gaucher acquired 17,200 shares of ProMetic Life Sciences stock in a transaction that occurred on Thursday, August 17th. The stock was acquired at an average cost of C$1.18 per share, with a total value of C$20,296.00.
Shares of ProMetic Life Sciences Inc. (TSE PLI) traded down 6.40% during trading on Thursday, reaching $1.17. 2,261,102 shares of the company were exchanged. ProMetic Life Sciences Inc. has a 1-year low of $1.13 and a 1-year high of $3.24. The firm has a 50-day moving average price of $1.57 and a 200-day moving average price of $2.00. The stock’s market capitalization is $782.39 million.
COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/17/prometic-life-sciences-inc-pli-director-nancy-orr-gaucher-purchases-17200-shares.html.
A number of equities analysts recently commented on the stock. Scotiabank reissued an “outperform” rating and issued a C$4.75 price objective on shares of ProMetic Life Sciences in a research note on Wednesday, April 19th. Royal Bank Of Canada reissued an “outperform” rating and issued a C$4.00 price objective on shares of ProMetic Life Sciences in a research note on Wednesday, April 19th. Canaccord Genuity reduced their price objective on shares of ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research note on Monday, June 19th. Finally, TD Securities reduced their price objective on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of C$4.07.
About ProMetic Life Sciences
ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.